Bronchogen

Bronchogen is a short synthetic peptide studied for repairing and normalizing bronchial epithelium, the lining of the airways. Most research describes the sequence as Ala-Asp-Glu-Leu, while one delivery-modeling study refers to the related sequence Ala-Glu-Asp-Leu Interaction of Ala-Glu-Asp-Leu Tetrapeptide Molecules with KRH and KHR Dendrimers in Water+1. It belongs to a peptide bioregulator research tradition that tests short tissue-specific peptides for effects on gene expression in specific tissues Peptide regulation of gene expression and protein synthesis in bronchial epithelium+1.

Early work showed short fluorescence-labeled peptides can enter the cell nucleus and interact with DNA Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. In rat models of obstructive lung pathology, peptide therapy produced anti-inflammatory and regenerative effects [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY] and improved the morphofunctional state of bronchial epithelium Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.

Bronchogen does not act through a single membrane receptor. The main finding is that short peptides of this class enter the nucleus and bind to DNA or chromatin, changing how tightly DNA is packaged and which genes are transcribed Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability+1. In bronchial epithelium, peptide treatment regulates gene expression and protein synthesis programs involved in epithelial repair Peptide regulation of gene expression and protein synthesis in bronchial epithelium. A related tetrapeptide also altered chromatin thermostability in vitro Influence of tetrapeptide on chromatin thermostability.

Secondary effects in an obstructive lung model include anti-inflammatory and regenerative actions [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+1. Tissue-specific bioregulator peptides can stimulate cell differentiation during aging, suggesting a repair axis rather than a direct cytokine block Peptides tissue-specifically stimulate cell differentiation during their aging. The precise transcription factors or response elements remain uncharacterized.

Documented effects are mostly from animal and in vitro models, not human trials.

• Obstructive lung pathology: In rats, peptide therapy produced anti-inflammatory and regenerative effects [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY], and bronchial epithelium showed improved morphofunctional state Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology.
• Gene regulation: In bronchial epithelium models, Bronchogen-related peptides regulated gene expression and protein synthesis Peptide regulation of gene expression and protein synthesis in bronchial epithelium.
• DNA and chromatin interaction: Bronchogen altered DNA thermostability Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability, and a related tetrapeptide changed chromatin thermostability Influence of tetrapeptide on chromatin thermostability.
• Nuclear penetration: Fluorescence-labeled short peptides entered HeLa cell nuclei and interacted with DNA Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.
• Differentiation: Tissue-specific peptides stimulated cell differentiation in aging models Peptides tissue-specifically stimulate cell differentiation during their aging.
• Plant model: Short exogenous peptides regulated CLE, KNOX1, and GRF family genes in tobacco, suggesting conserved gene-regulatory activity Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum.

No human efficacy data exist.

Published research protocols are mostly community or practitioner consensus because no human RCTs define dosing. Animal studies used multi-day peptide courses in obstructive lung models [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+1, but exact doses are not abstracted.

Community and practitioner protocols commonly describe:

• Subcutaneous: 50–100 mcg once daily for 10–20 days.
• Weight-scaled practitioner consensus: 2 mcg/kg once daily for 10–14 days.
• Intensive lung-support: 100 mcg once daily for 20 days, with repeat cycles about every 3 months.

Fixed dosing is usually 50–100 mcg/day. Body-weight-adjusted dosing has not been validated in controlled human studies.

Bronchogen is typically supplied as lyophilized powder. The default diluent is bacteriostatic water containing 0.9% benzyl alcohol; sterile water may be used for single-use applications. Add the diluent slowly down the vial wall and roll gently rather than shaking.

Lyophilized powder should be stored at about −20 °C for long-term stability, or at 2–8 °C for short-term use. Reconstituted solution should be refrigerated at 2–8 °C and used within 14–28 days. Bacteriostatic water supports multi-dose use; preservative-free sterile water solutions should be used within 24–48 hours.

Use the interactive reconstitution calculator on this page for concentration and volume calculations.

No formal human drug-drug interaction studies exist for Bronchogen. The available interaction profile is based on animal and in vitro work [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+2.

• Corticosteroids: Low-theoretical overlap with anti-inflammatory transcriptional effects; monitor lung function in steroid-dependent obstructive lung disease [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+1.
• Bronchodilators: No shared receptor or metabolic pathway identified; standard monitoring.
• Biologics and immunosuppressants: Moderate-theoretical additive immunomodulation; specialist supervision recommended.
• Anticoagulants and antiplatelets: No known coagulation effect; standard injection precautions.

For supplements, high-dose anticoagulant/antiplatelet supplements may add bleeding risk at injection sites. Antioxidants and immunomodulatory supplements have no expected adverse interaction.

No tolerance or withdrawal data exist for Bronchogen. Cycling follows bioregulator convention rather than RCT evidence.

• Standard injectable: 50–100 mcg once daily by subcutaneous route for 10 days, then off 3–6 months.
• Lower-dose extended: 50–100 mcg daily for 20–30 days, with 4–6 weeks between cycles.
• Repeat course: 10–20 days, with minimum 3 months after the prior full course.

The rationale is that Bronchogen alters DNA/chromatin thermostability and bronchial gene expression Peptide regulation of gene expression and protein synthesis in bronchial epithelium+1, so intermittent courses deliver repeated transcriptional pulses. Signs a break may be needed include no further improvement after a completed course, worsening symptoms despite the protocol, accumulating injection reactions, or two consecutive cycles without benefit.

No formal peptide-peptide interaction studies exist for Bronchogen. Practitioner consensus guides combinations.

• Khavinson bioregulators (Epitalon, Vilon, Thymogen): commonly combined in tissue-specific protocols; no adverse interactions documented.
• Healing peptides (BPC-157, TB-500): theoretical synergy on epithelial repair; co-administration appears low-risk in community practice.
• GLP-1 receptor agonists (semaglutide, tirzepatide): no shared pathways; no expected interaction.
• GH secretagogues (CJC-1295, ipamorelin): no direct mechanistic conflict reported.

Bronchogen is not FDA approved. It is an experimental unapproved new drug in the United States, and it is not listed in any Controlled Substances Act schedule. It lacks a USP/NF monograph, so 503A compounding pharmacies cannot lawfully compound it.

The animal evidence behind Bronchogen comes mostly from Russian peptide bioregulator research [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+2. Outside the US, EMA, MHRA, and TGA have no licensed Bronchogen product. No WADA or anti-doping status is reported in the available sources.

No formal human adverse-event incidence data exist. Preclinical animal studies report anti-inflammatory and regenerative effects without documented systemic toxicity [ANTIINFLAMMATORY AND REGENERATIVE EFFECT OF PEPTIDE THERAPY IN THE MODEL OF OBSTRUCTIVE LUNG PATHOLOGY]+1.

• Common reported effects: injection-site irritation, mild fatigue or headache, and transient cough or increased sputum during the first 3–5 days. These usually resolve without dose change.
• Uncommon effects: transient worsening of cough in chronic bronchitis, dizziness with rapid injection, and occasional nausea. Usually self-limiting.
• Theoretical risks: hypersensitivity reaction, excessive epithelial proliferation, autoimmune activation, and off-target chromatin effects. None are confirmed in available sources.

Contraindications include known hypersensitivity to Bronchogen, active lung malignancy, acute febrile respiratory infection, severe hepatic or renal impairment, and pregnancy or breastfeeding.